Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Introduction Plasma phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aβ42/40) may have diagnostic and prognostic value in Alzheimer's disease (AD). Here we assess which markers can best identify AD from controls and other non-AD dementias in a large international multi-center study. Methods Plasma samples (n = 1298) were collected from six international centers. Aβ40, Aβ42, GFAP, NfL, and p-tau181 were measured using single molecule array. In each group, AD diagnosis/co-pathology was defined according to cerebrospinal fluid biomarkers or amyloid positron emission tomography. Validations were performed in three separate cohorts via single and dual cut-off models. Results p-tau181 showed the best area under the curve value to separate AD from frontotemporal dementia, controls, and Aβ- dementia with Lewy bodies. However, this discriminative power could not be reproduced by applying pre-defined cut-offs. Discussion p-tau181 was the best single plasma marker for detecting AD at any stage. Specific cut-offs are needed to maximize diagnostic performances. Highlights Phosphorylated tau (p-tau)181 provided a clear differentiation between controls and Alzheimer's disease (AD) participants, with evidence of increased levels in the preclinical stage of AD. Plasma biomarkers demonstrated that when amyloid co-pathology is removed from dementia with Lewy bodies (DLB), only glial fibrillary acidic protein and neurofilament light chain remain to predict DLB. Given the low prevalence of amyloid co-pathology in frontotemporal dementia (FTD), p-tau181 and its ratio with amyloid beta 42 are strong biomarkers to differentiate FTD from AD.

What this study adds

Evidence grade: Moderate

This is a cross-sectional study of 1,298 participants. The authors conclude that specific cut-offs are needed to maximize diagnostic performance, so this is about diagnosis rather than treatment, cure, or prevention. Its stated limit: Kit-lot differences between cohorts could not be bridged, so validation AUCs may be underestimated; subgroup sizes for MCI due to FTD and DLB were small; validation groups were limited in size, and a uniform international cut-off may not be achievable with these biomarkers.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Doecke, J. D., Bellomo, G., Vermunt, L., Alcolea, D., Halbgebauer, S., In 't Veld, S., et al. (2025). Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: An international multi-center study. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14573

Vancouver

Doecke JD, Bellomo G, Vermunt L, Alcolea D, Halbgebauer S, In 't Veld S, et al. Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: An international multi-center study. Alzheimer's & Dementia. 2025. doi:10.1002/alz.14573. PMID: 40551285.

BibTeX

@article{doecke2025-40551285,
  author  = {Doecke, J. D. and Bellomo, G. and Vermunt, L. and Alcolea, D. and Halbgebauer, S. and In 't Veld, S. and Mattsson-Carlgren, N. and Veverova, K. and Fowler, C. J. and Boonkamp, L. and Houtkamp, I. M. and Koel-Simmerlink, M. and others},
  title   = {{Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: An international multi-center study}},
  journal = {Alzheimer's \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.14573},
  pmid    = {40551285},
  url     = {https://doi.org/10.1002/alz.14573}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In this cross-sectional international multi-center study of 1298 plasma samples, p-tau181 showed the best area under the curve for separating Alzheimer's disease from frontotemporal dementia, controls, and Aβ- dementia with Lewy bodies, but this discriminative power could not be reproduced using pre-defined cut-offs. The authors conclude that specific cut-offs are needed to maximize diagnostic performance, so this is about diagnosis rather than treatment, cure, or prevention.

Study details

Limitations

Kit-lot differences between cohorts could not be bridged, so validation AUCs may be underestimated; subgroup sizes for MCI due to FTD and DLB were small; validation groups were limited in size, and a uniform international cut-off may not be achievable with these biomarkers.

How this study scored 52/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record left out, no data; Study design 4 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 4 of 4; Institution's track record left out, no data; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 47 of the 91 points it could be judged on, which is 52 of 100. Total 52 of 100.47 of the 91 points we could judge = 52 of 100

Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, institution's track record and free to read, so those were left out: it earned 47 of the 91 points we could judge it on, which is 52 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Alzheimer's & Dementia)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 4 / 12 A snapshot of people at one point in time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 3 / 4 1,298 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 3 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.0 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 1.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Charlotte Elisabeth Teunissen: h-index 116 (OpenAlex, whole career)
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40551285)
Free to read — / 2 Access not recorded — left out of this score
Points 47 / 91 Scored on 17 of 20 parts. We have no data for the rest, so they are left out: 47 of the 91 points we could judge it on is 52 out of 100.
Total 52 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →